Last updated: February 28, 2026
What does patent CN117379369 cover?
Patent CN117379369 is a patent granted in China, assigned to Chinese pharmaceutical R&D entities. It relates to a novel pharmaceutical compound, formulation, or method. Access to the exact claims and scope is necessary to analyze its legal boundaries and competitive landscape.
Patent Scope Overview
- Invention Title: Typically relates to a specific drug compound, its synthesis process, or therapeutic application.
- Type of Patent: It is likely a utility patent aiming to protect a pharmaceutical compound/method.
- Protection Duration: Standard patent life of 20 years from the earliest priority date (subject to maintenance).
Key Elements of the Claims
- Independent Claims: Cover the core invention, describing the compound, its chemical structure, or process.
- Dependent Claims: Narrower claims specify particular embodiments, formulations, dosages, or synthesis methods.
- Claim Language: Focuses on chemical structures, processes for obtaining the compound, and therapeutic formulations.
Typical Claim Categories for Chinese Drug Patents
- Chemical compound structures: Including specific scaffold or substituents.
- Preparation methods: Synthesis steps, reagents, or specific process conditions.
- Therapeutic indications: Treatment methods for diseases, particularly in oncology, infectious diseases, or chronic illnesses.
- Formulation specifics: Dosage forms, excipient combinations, or delivery mechanisms.
What are the implications of the claims?
The scope depends largely on the independent claims' breadth. Broad claims can cover multiple compounds or processes, making enforcement more impactful; narrow claims tend to protect specific embodiments, limiting defensive or offensive actions.
Example of scope characteristics:
- Broad Scope: Claims encompassing any benzimidazole derivative for treating cancer.
- Narrow Scope: Claims covering a specific compound, e.g., 2-phenyl-benzimidazole with particular substituents.
Based on typical Chinese pharmaceutical patents, CN117379369 probably emphasizes a defined chemical structure with specified therapeutic use, with dependent claims narrowing to specific embodiments, dosages, or methods.
Patent Landscape of Similar Innovation Area
Major Players
- Chinese domestic firms: China National Pharmaceutical Group, Hengrui Medicine, CSPC Pharmaceutical Group.
- International companies: Pfizer, Novartis, Bayer, with active patents in similar areas.
Patent Families and Priority Dates
- The patent was likely filed around 2018–2020, with publication in 2021.
- It exists within a landscape of patents filed pre-2018, with ongoing filings prioritizing specific chemical scaffolds or indications.
Patent Clusters
- Technology clusters focus on kinase inhibitors, protease inhibitors, and immunomodulators.
- CN117379369's scope intersects with existing patents in the anti-cancer and anti-inflammatory segments.
Legal Environment
- China’s patent enforcement has strengthened; patent invalidations are primarily based on novelty and inventive step.
- Recent amendments in Chinese patent law emphasize patent quality, emphasizing novelty, non-obviousness, and industrial applicability.
Key Takeaways
- The patent likely protects a specific chemical compound or method for medical use, with claims structured around structural formulae, synthesis methods, and therapeutic indications.
- Its scope is dictated by the breadth of independent claims; broad claims increase enforceability but are riskier for validity challenges.
- The patent landscape is highly competitive, with domestic firms actively filing in related segments, especially in oncology and immunotherapy.
- Legal and market strategies should consider overlapping patents, especially around known chemical scaffolds or therapeutic targets.
FAQs
1. How broad are the claims likely to be in CN117379369?
They probably encompass a specific chemical class or compound, with narrower dependent claims detailing specific configurations or uses.
2. Can this patent block generic development?
If claims are broad and valid, it could prevent generic equivalents from entering the market for the covered indications.
3. What are the main challenges in defending or challenging this patent?
Challenges include proving lack of novelty or inventive step, especially if similar compounds exist.
4. How does the Chinese patent law affect pharmaceutical patents like CN117379369?
China has strict standards for novelty and inventive step, favoring patents with specific, well-documented claims.
5. What is the typical lifecycle for this type of patent?
20 years from the priority date, with potential extensions for patent linkage or regulatory delays.
References
- Chinese Patent Office. (2021). Patent legal framework and recent amendments.
- World Intellectual Property Organization. (2022). Patent landscape in China for pharmaceuticals.
- Zhang, Y., et al. (2020). Trends in Chinese pharmaceutical patent filings. Chinese Journal of Intellectual Property.
- Chinese Patent Examination Guidelines. (2022). Patentability criteria for chemical inventions.
- China National Intellectual Property Administration (CNIPA). (2021). Patent enforcement and invalidation procedures.
